Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas has acquired 647,809 common shares valued at $425,000 through six transactions between December 20, 2024, and January 17, 2025. Following these purchases, Siokas's beneficial ownership in the company has increased to 4,164,789 common shares.
The CEO expressed enthusiasm about the company's future prospects and highlighted his continued commitment, noting his total personal investment of over $17 million since the company's inception. Siokas emphasized that Cosmos Health is at a transformative moment, focusing on advancing their strategy, driving projects forward, and expanding their brands globally.
Positive
- CEO increases stake with $425,000 worth of shares purchase
- CEO demonstrates confidence with total personal investment exceeding $17 million
- Insider buying indicates management's positive outlook on company's future
Negative
- None.
Insights
The recent accumulation of 647,809 shares by CEO Greg Siokas, valued at
The purchase pattern is particularly noteworthy - six separate transactions over 32 days suggests a methodical accumulation strategy rather than a single bulk purchase. This approach often indicates a careful consideration of market dynamics and potentially helps minimize price impact while building a position.
For micro-cap healthcare companies like Cosmos Health (market cap:
The timing of these purchases aligns with Cosmos Health's strategic initiatives in pharmaceutical distribution, nutraceuticals and telehealth expansion. While micro-cap healthcare stocks typically carry higher risk profiles, strong insider buying often precedes corporate developments or operational improvements that management believes will enhance shareholder value.
These transactions have occurred in a concentrated timeframe, suggesting a high conviction move rather than routine portfolio management. However, investors should note that while insider buying is generally a positive signal, it should be considered alongside other fundamental and technical factors in any investment decision.
CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at
As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.
Greg Siokas, CEO of Cosmos Health, stated: "I am incredibly excited about our future prospects and remain deeply committed to supporting Cosmos, having personally invested over
Information on Mr. Siokas's Recent Transactions:
Please refer to the filings on Form 4 filed with the SEC and available on the SEC's website for more information about the nature of the transactions, including details such as "Ownership Form", "Transaction Date", "Amount", "Price", and other relevant information regarding the shares acquired by Mr. Siokas.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
How many shares did Cosmos Health CEO Greg Siokas purchase in recent transactions (COSM)?
What is Greg Siokas's total ownership in Cosmos Health (COSM) after recent purchases?
How much has Greg Siokas invested in total in Cosmos Health (COSM)?
When did the recent share purchases by Cosmos Health CEO occur (COSM)?
